News

Tattoo science goes skin deep, from ink placement and healing to adverse reactions, aftercare, and the dermatologic effects of pigment.

This review of the latest dermatological studies includes insights on brodalumab for plaque psoriasis, physiological characteristics of scalps with high sebum production, disease burden of anogenital PsO, and more.

Jennifer Song, MD, discussed icotrokinra, expanding pediatric psoriasis options, emerging TYK2 inhibitors, and GLP-1 combination data.

Daniel Butler, MD, discussed how aging affects psoriasis presentation and the insurance challenges facing older patients in a recent Dermatology Times interview.

Judson Brewer, MD, PhD, discussed how the trigger-behavior-result habit loop model can be applied to itch-scratch cycles in atopic dermatitis.

GBD 2021 shows urticaria burden in the Middle East and North Africa has stayed flat for 3 decades, but rates vary widely based on location, gender, age, and more.

LEO Pharma will acquire worldwide rights to dersimelagon, an investigational oral therapy under FDA review for EPP and XLP.

In the August letter from the editor in chief, Christopher Bunick, MD, PhD, explains bemotrizinol’s broad-spectrum UVA/UVB benefits and simple UV safety habits for sunscreen, pools, and wounds.

Social media skin care trends drive excess product use, skin barrier damage, delayed dermatologist visits, and worse acne—especially among TikTok and influencer-following users.

Learn how dermatologists can pinpoint causes of scarring vs nonscarring hair loss, avoid biotin pitfalls, and choose personalized treatments early.

Our August issue tackles psoriasis, acne, aesthetics, sunscreen safety, and more.

Oral peptide pills are reshaping psoriasis care, from semaglutide breakthroughs to IL‑23 blocker icotrokinra—here's what dermatologists need to know now.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Updated Allergan Partner Privileges offers simplified savings, greater benefits transparency, portfolio-level rewards, and a new BOTOX Cosmetic growth rebate.

Are pimple patches really that effective in clearing acne or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Review 10 evidence-based answers on GPP pathophysiology, diagnosis, and IL-36-targeted management, drawn from National Psoriasis Foundation consensus and emergency medicine literature.

Persistent hives with throat tightness and abdominal pain suggest C1‑INH deficiency in chronic spontaneous urticaria—see when complement tests point to HAE.

According to new research, AI reads real-world smartphone photos to score 4 eczema severity signs, boosting EASI training accuracy and reducing rater variability.

Oyetewa Asemba, MD, discussed common mistakes in hair loss and pigmentary disorder care, from scalp exams to treatment vehicle selection.

Aaron Farberg, MD, outlines common triggers of generalized pustular psoriasis flares and the role of IL-36 targeted therapy.

At a Dermatology Times Case-Based Roundtable in Las Vegas, Nevada, clinicians compared topical corticosteroids, newer nonsteroidal agents, and systemic therapy across adult and adolescent AD cases.

Aaron Farberg, MD, reviews the diagnostic challenges of generalized pustular psoriasis and its common mimics across care settings.

Eileen Cheever, PA, discussed family hesitancy toward systemic pediatric psoriasis treatment and age-related treatment gaps in dermatology.

Aaron Farberg, MD, discusses why generalized pustular psoriasis warrants its own awareness day and how it differs immunologically from plaque psoriasis.

An MCC case illustrates how travel distance and limited oncology access can influence treatment decisions and adherence in rural patients.

Oral JAK1 povorcitinib shows manageable adverse acne and strong responses even after biologic failure, offering an alternative to injections.

Jerry Shapiro, MD, explains VDPHL01's cardiac safety profile and patient-reported outcomes in a phase 2 trial for female pattern hair loss.

This review of the latest dermatological studies includes insights on JAKs in severe HS, reactive cutaneous capillary endothelial proliferation in esophageal SCC, PN treatment preferences, and more.

Karen McGuire, PhD, CEO and co-founder of BioMendics, discusses TAMES-02 phase 2 trial enrollment and a new blister burden end point in EBS.

Lisa Swanson, MD, FAAD, discussed expanding oral JAK inhibitor options for younger children with atopic dermatitis and alopecia areata.